替奈普酶在急性缺血性卒中再灌注治疗中的研究进展  

Recent advance in tenecteplase in acute ischemic stroke reperfusion

作　　者：赵耀 钟海龙 Zhao Yao;Zhong Hailong(Department of Cerebrovascular Diseases Huizhou First People's Hospital Huizhou 516000,China;Department of Neurosurgery,Beijing Neurosurgical Institute,Beijing Tiantan Hospital,Capital Medical University,Beijing 100050,China)

机构地区：[1]惠州市第一人民医院脑血管病科,惠州516000 [2]首都医科大学北京市神经外科研究所,首都医科大学附属北京天坛医院神经外科,北京100050

出　　处：《中华神经医学杂志》2024年第10期1050-1054,共5页Chinese Journal of Neuromedicine

摘　　要：卒中是我国成年人致残率、致死率最高的疾病,给社会和家庭带来沉重的负担。近年来,第三代溶栓药物替奈普酶在急性缺血性卒中再灌注治疗的多个领域取得突破性进展,陆续被国内外指南推荐用于急性缺血性卒中的静脉溶栓或血管内取栓前的桥接取栓。2024年欧洲卒中组织会议公布了多个关于替奈普酶的大型临床试验结果,为替奈普酶在急性缺血性卒中再灌注治疗提供更多的循证医学证据。本文对替奈普酶在急性缺血性卒中再灌注治疗中的最新研究进行综述,同时对该领域未来的研究方向进行展望,以期为临床医师的临床实践和进一步开展相关临床研究提供参考。Stroke has the highest morbidity and mortality in the adults of China,with heavy burden to the society and family.In recent years,the third generation of thrombolytic drug tenecteplase has made breakthrough in many fields of acute ischemic stroke reperfusion,and has been recommended by domestic and foreign guidelines for intravenous thrombolysis or intravenous thrombolysis bridging to mechanical thrombectomy for acute ischemic stroke.Results of several large clinical trials of tenecteplase have been published in the European Stroke Organization Conference in 2024,which provides more evidence-based medical evidences for tenecteplase in acute ischemic stroke reperfusion.This article reviews the latest research on tenecteplase in acute ischemic stroke reperfusion,and looks forward to the future direction of this field,in order to provide some references for clinicians and further related clinical study using tenecteplase.

关 键 词：替奈普酶 急性缺血性脑卒中 再灌注治疗 静脉溶栓 血管内取栓 

分 类 号：R743.3[医药卫生—神经病学与精神病学]